An Evaluation of the AeriSeal System for CONVERTing Collateral Ventilation Status in Patients With Severe Emphysema (CONVERT_II)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT06035120 |
Recruitment Status :
Recruiting
First Posted : September 13, 2023
Last Update Posted : April 23, 2024
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Emphysema, Pulmonary Emphysema or COPD | Device: AeriSeal System | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 200 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Intervention Model Description: | The study is designed as a single-arm clinical trial in which eligible subjects with an identified fissure gap in the target lobe will be treated with the AeriSeal System to determine the rate of conversion from having collateral ventilation (CV+) to having little to no collateral ventilation (CV-). Subjects who convert to CV- status with AeriSeal will then undergo BLVR using Zephyr Valve per standard of care. |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | An Evaluation of the AeriSeal System for CONVERTing Collateral Ventilation Status in Patients With Severe Emphysema: The CONVERT II Trial |
Actual Study Start Date : | February 22, 2024 |
Estimated Primary Completion Date : | June 30, 2027 |
Estimated Study Completion Date : | March 31, 2028 |
Arm | Intervention/treatment |
---|---|
Experimental: AeriSeal
All enrolled subjects meeting final eligibility will undergo the AeriSeal procedure to block collateral ventilation by closing the lobar fissure gaps or collateral air channels.
|
Device: AeriSeal System
The AeriSeal System comprises AeriSeal Foam and the AeriSeal Balloon Catheter Preparation Kit that is used for bronchoscopic delivery of AeriSeal Foam to the targeted regions of the lung. |
- Converters, responder rate [ Time Frame: 45 days post-AeriSeal treatment (index or repeat) ]The percentage of study subjects that successfully convert from a positive collateral ventilation status (CV+) in the treated lobe to having little to no collateral ventilation (CV-) by Chartis.
- Post-bronchodilator forced expiratory volume in 1 second (FEV1), responder rate [ Time Frame: Month 6 post-Zephyr Valve ]The percentage of converters achieving a ≥ 12% increase in FEV1
- Residual volume (RV), responder rate [ Time Frame: Month 6 post-Zephyr Valve ]The percentage of converters achieving a ≥ 310 mL decrease in RV
- Treated lobe volume reduction (TLVR) by high-resolution computed tomography (HRCT), responder rate [ Time Frame: Month 6 post-Zephyr Valve ]The percentage of converters achieving a ≥ 350 mL decrease in TLVR
- St. George's Respiratory Questionnaire (SGRQ), responder rate [ Time Frame: Month 6 post-Zephyr Valve ]The percentage of converters achieving a ≥ 4-point decrease in SGRQ total score
- Post-bronchodilator forced expiratory volume in 1 second (FEV1) change [ Time Frame: Month 3, Month 6, Month 12, Month 24 ]Absolute, percent and percent predicted change
- Post-bronchodilator forced expiratory volume in 1 second (FEV1), responder rate [ Time Frame: Month 3, Month 12, Month 24 ]Percentage of subjects achieving a ≥12% increase
- Residual volume (RV), responder rate [ Time Frame: Month 3, Month 12, Month 24 ]The percentage of subjects achieving a ≥ 310 mL decrease in RV
- Residual volume (RV), change [ Time Frame: Day 45, Month 6, Month 12 ]Absolute and percent predicted change in RV
- Treated lobe volume reduction (TLVR) by high-resolution computed tomography (HRCT), change [ Time Frame: Day 45, Month 6, Month 12 ]Absolute change in TLVR
- Treated lobe volume reduction (TLVR) by high-resolution computed tomography (HRCT), responder rate [ Time Frame: Day 45, Month 12 ]The percentage of subjects achieving a ≥ 350 mL decrease in TLVR
- Residual volume to total lung capacity (RV/TLC) ratio [ Time Frame: Month 3, Month 6, Month 12, Month 24 ]Absolute change in RV/TLC ratio
- Forced vital capacity (FVC), change [ Time Frame: Month 3, Month 6, Month 12, Month 24 ]Absolute and percent change in FVC
- Diffusion capacity of carbon monoxide (DLCO), change [ Time Frame: Month 6, Month 12 ]Absolute and percent predicted change in DLCO
- Chronic Obstructive Pulmonary Disease assessment test (CAT), change [ Time Frame: Month 3, Month 6, Month 12 ]Absolute change. Minimum score: 0, maximum score: 40. Lower scores indicate a better outcome.
- Chronic Obstructive Pulmonary Disease assessment test (CAT), responder rate [ Time Frame: Month 3, Month 6, Month 12 ]The percentage of subjects achieving a ≥ 2-point decrease
- St. George's Respiratory Questionnaire (SGRQ), total score change [ Time Frame: Month 3, Month 6, Month 12 ]Absolute change in SGRQ total score. Minimum score: 0, maximum score: 100. Lower scores indicate a better outcome.
- St. George's Respiratory Questionnaire (SGRQ), responder rate [ Time Frame: Month 3, Month 12 ]The percentage of converters achieving a ≥ 4-point decrease in SGRQ total score
- Six Minute Walking Test (6MWT), responder rate [ Time Frame: Month 6, Month 12 ]Percentage of subjects achieving a ≥ 26 meter increase
- Modified Medical Research Council (mMRC) Dyspnea Scale, total score change [ Time Frame: Month 3, Month 6, Month 12 ]Absolute change in total mMRC Dyspnea Scale score. Minimum score: 0, maximum score: 4. Lower scores indicate a better outcome.
- Modified Medical Research Council (mMRC) Dyspnea Scale, responder rate [ Time Frame: Month 3, Month 6, Month 12 ]The percentage of subjects achieving a ≥ 1-point decrease
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 22 Years to 80 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Subject is willing and able to provide informed consent and to participate in the study.
- Subject is aged ≥ 22 and ≤ 80 years at the time of the ICF signature date.
- Subject has completed a documented pulmonary rehabilitation (in clinic or home-based) program within 6 months prior to Baseline.
- Subject has stopped smoking for at least 8 weeks prior to the ICF signature date as confirmed by carboxyhemoglobin or cotinine levels.
-
Subject has an HRCT from the screening institution within 3 months of the ICF signature date with the following findings at -910 Hounsfield Units:
- At least one (1) lobe with segmental emphysema destruction score ≥ 50%.
- Subject has heterogenous emphysema, defined as difference in emphysema destruction score of ≥ 15 between the density scores of the target lobe and the ipsilateral non-target lobe(s) per QCT report with % voxel density of < -910 HU. For non-target lobes that include the RML, calculate the combination of non-target lobes as a single density score using volume-weighted percent.
- LUL, LLL, RUL, RLL, or RUL+RML are targets for valve intervention.
- Subject has a gap in the interlobar fissure that corresponds to one or more segments and the fissure(s) contacting the target lobe is ≥ 80% complete per QCT report.
- Subject has 98% of the fissure gap confined to a maximum of 3 segments within the target lobe per Fissure Targeting Report (FTR).
- Subject has 6MWD ≥ 250 m and ≤ 450 m.
- Subject has clinically significant dyspnea with an mMRC score of ≥ 2.
- Subject has post-bronchodilation FEV1 ≥ 15% predicted and ≤ 45% predicted.
- Subject has an FEV1/FVC ratio of < 0.7.
- Subject has post-bronchodilation TLC, measured by body plethysmography, ≥ 100% predicted.
- Subject has post-bronchodilation RV ≥ 175% predicted, measured by body plethysmography.
- Subject has post-bronchodilation DLCO ≥ 20% predicted.
- Subject has received preventative vaccinations against potential respiratory infections, including COVID-19, consistent with local recommendation or policy.
- Subject is on optimal medical management for more than one month prior to the ICF signature date.
- Subject has collateral ventilation (CV+) as confirmed per the Chartis assessment prior to the AeriSeal Index Procedure.
Exclusion Criteria:
- Subject has prior lung volume reduction surgery, lobectomy or pneumonectomy, lung transplantation, airway stent placement, pleurodesis, or BLVR of any type, except BLVR using Zephyr Valve with < 50% TLVR at 6 months, followed by valve removal > 6 months prior to ICF signature date.
- Subject has visible radiological abnormality on HRCT scan such as pulmonary nodule greater than 0.8 cm in diameter (does not apply, if present for 2 years or more without increase in size or if deemed benign by biopsy) or active pulmonary infection (e.g., unexplained parenchymal infiltrate, significant interstitial lung disease or significant pleural disease).
- Post-COVID-19 pathology on CT, including ground glass opacities with or without consolidation, adjacent pleura thickening, interlobular septal thickening, or air bronchograms.
- Large bullae encompassing greater than 1/3 of the total lung.
- Subject had 3 or more COPD exacerbations requiring hospitalization within 12 months preceding the ICF signature date or a COPD exacerbation requiring hospitalization within 8 weeks of the ICF signature date. Subjects may be re-considered for future enrollment.
- Subject has asthma as their primary diagnosis.
- Subject has chronic bronchitis (defined as greater than 4 tablespoons of sputum production per day) as their primary diagnosis.
- Subject has clinically significant bronchiectasis.
- Subjects with evidence of active respiratory infection should be considered for enrollment only after satisfactory resolution.
- Subject requires invasive ventilatory support. Note: The use of Continuous Positive Airway Pressure (CPAP) or BiPAP devices for sleep apnea is permitted.
-
Subject has severe gas exchange abnormalities as defined by any one of the following tests, conducted at rest, on room air, as tolerated.
- PaCO2 ≥ 50 mm Hg (7.3 kPa)
- PaO2 < 45 mm Hg (6.0 kPa)
- Subject has pulmonary hypertension, defined as mean pulmonary systolic pressure > 45 mm Hg.
- Subject has known documented alpha-1 antitrypsin deficiency.
- Subject has clinically significant hematological disorder.
- Subject has recent significant unplanned or unexplained weight loss or other relevant comorbidities considered by the investigator to be potentially confounding or limiting to the subject's participation in the study.
- Subject has non-atrial arrhythmias or conduction abnormalities on EKG.
- Subject has high cardiac risk after undergoing cardiac risk assessment in accordance with published guidelines (Fleisher 2007) or has ischemic heart disease, congestive heart failure, cerebrovascular disease (stroke or TIA within 6 months of the ICF signature date), or serum creatinine > 2.0 mg/dL (177 μmol/L).
- Subject has uncontrolled exercise induced syncope.
- Subject has evidence of severe disease which in the judgment of the investigator may compromise the anticipated treatment effect or the subject's survival for the duration of at least 12 months.
- Subject has any other condition that the investigator believes would interfere with the intent of the study or would make participation not in the best interest of the subject including but not limited to alcoholism, high risk for drug abuse, or noncompliance in returning for follow-up visits.
- Subject cannot tolerate corticosteroids or relevant antibiotics.
- Subject use of systemic corticosteroids > 20 mg/day prednisolone or equivalent within four (4) weeks of the ICF signature date. Subjects may be re-considered for future enrollment.
- Subject use of immunosuppressive agents within four (4) weeks of the ICF signature date. Subjects may be re-considered for future enrollment.
- Subject is unable to temporarily discontinue heparins and oral anticoagulants (e.g., warfarin, dicumarol) according to local pre-procedural protocols. Note: Antiplatelet drugs including aspirin, thienopyridines and ticagrelor are permitted.
- Subject has allergy or sensitivity to medications required to safely perform bronchoscopy under conscious sedation or general anesthesia.
- Subject has known allergy to the following device components: Polyether block amide (PEBAX), Polyvinyl Alcohol or Glutaraldehyde, Nitinol (nickel-titanium) or its constituent metals (nickel or titanium) or Silicone.
- Subject is a female who is pregnant (positive βHCG Pregnancy test), breast-feeding, or planning to be pregnant in the next 12 months.
- Subject has Body Mass Index < 18 kg/m2 or > 35 kg/m2.
- Subject participated in an investigational study of a drug, biologic, or device not currently approved for marketing within 30 days prior to the ICF signature date. Note: Subjects being followed as part of a long-term surveillance of a non-pulmonary study that has reached its primary endpoint are eligible for participation in this study.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT06035120
Contact: Christina Kutzavitch, PhD | +1 650-216-0134 | ckutzavitch@pulmonx.com | |
Contact: Joshua Percy | +1 650-810-1420 | jpercy@pulmonx.com |
Australia | |
Macquarie University | Recruiting |
Macquarie Park, Australia | |
Contact: Alvin Ing, MD alvin.ing@mq.edu.au | |
Principal Investigator: Alvin Ing, MD | |
Germany | |
Ruhrlandklinik - West German Lung Center | Recruiting |
Essen, Germany, 45239 | |
Contact: Kaid Darwiche, MD +49 201/ 433 4222 kaid.darwiche@rlk.uk-essen.de | |
Contact: Birte Schwarz +49 201/ 433 4699 Birte.Schwarz@rlk.uk-essen.de | |
Universitätsklinikum Halle | Recruiting |
Halle, Germany | |
Contact: Stephan Eisenmann, MD stephan.eisenmann@uk-halle.de | |
Principal Investigator: Stephan Eisenmann, MD | |
Asklepios Klinik Barmbek | Recruiting |
Hamburg, Germany, 22307 | |
Contact: Ralf Eberhardt, MD r.eberhardt@asklepios.com | |
Principal Investigator: Ralf Eberhardt, MD | |
Thoraxklinik am Universitats klinikum Heidelberg | Recruiting |
Heidelberg, Germany, 69126 | |
Contact: Felix Herth, MD Felix.Herth@med.uni-heidelberg.de | |
Principal Investigator: Felix Herth, MD | |
Italy | |
ASST Spedali Civili, University Hospital | Recruiting |
Brescia, Italy, 25123 | |
Contact: Michela Bezzi, MD michela.bezzi@asst-spedalicivili.it | |
Principal Investigator: Michela Bezzi, MD | |
Spain | |
Hospital Universitario y Politecnico La Fe | Recruiting |
Valencia, Spain, 46026 | |
Contact: Enrique Cases Viedma, MD cases_enr@gva.es | |
Principal Investigator: Enrique Cases Viedma, MD |
Study Director: | Anna K Gawlicka, PhD, MBA | Pulmonx Corporation |
Responsible Party: | Pulmonx Corporation |
ClinicalTrials.gov Identifier: | NCT06035120 |
Other Study ID Numbers: |
630-2000-01 |
First Posted: | September 13, 2023 Key Record Dates |
Last Update Posted: | April 23, 2024 |
Last Verified: | April 2024 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Plan Description: | All data will be aggregated and analyzed. No IPD be made available for sharing to other researchers. |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | Yes |
Device Product Not Approved or Cleared by U.S. FDA: | Yes |
Collateral Ventilation Bronchoscopic Lung Volume Reduction Hyperinflation |
Pulmonary Emphysema Emphysema Pathologic Processes Pulmonary Disease, Chronic Obstructive Lung Diseases, Obstructive |
Lung Diseases Respiratory Tract Diseases Chronic Disease Disease Attributes |